BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:38 PM
 | 
May 21, 2008
 |  BC Extra  |  Clinical News

Aflibercept misses ovarian cancer endpoint

Regeneron (NASDAQ:REGN) and sanofi-aventis (Euronext:SAN; NYSE:SNY) said aflibercept ( VEGF Trap) missed the primary endpoint in a Phase II trial to treat advanced ovarian cancer. The...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >